The Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) by eight companies/universities/institutes. The top development phase for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) is preclinical with three drugs in that stage. The Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline products market are: Boehringer Ingelheim International, Fujimoto Pharmaceutical and Laboratoires Delbert.
The key targets in the Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline products market include Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, and Fibroblast Growth Factor Receptor 3.
The key mechanisms of action in the Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline product include Protein Kinase B Inhibitor with one drug in Phase I. The Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline products market including Small Molecule, and Monoclonal Antibody.
Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) overview
Hereditary hemorrhagic telangiectasia (HHT) is also known as Osler-Weber-Rendu disease. It is an autosomal dominant disorder characterized by multiple mucocutaneous telangiectasias. These telangiectasias represent small arterio-venous malformations that frequently tend to bleed, causing the patient a significant amount of distress in their daily lives. Symptoms may include nose bleeds, gastrointestinal (GI) bleeds, and iron deficiency anemia.
For a complete picture of Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
